Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension (PAH). While details have not been disclosed, management has noted that the data, collected
